Rituximab
Based on 14 publication(s) in Google Scholar
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.50%
- CAS No.: 174722-31-7
- Masse moléculaire:143.47 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Rituximab
More- Signal Transduct Target Ther. 2020 Sep 14;5(1):200. [Abstract]
- EBioMedicine. 2024 Nov:109:105379. [Abstract]
- Cancer Biol Med. 2020 Nov 15;17(4):1026-1038. [Abstract]
- Clin Transl Med. 2025 May;15(5):e70336. [Abstract]
- Anal Chem. 2023 Apr 25;95(16):6700-6708. [Abstract]
- Anal Chim Acta. 2021 Apr 15:1154:338306. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101416. [Abstract]
- Bioconjug Chem. 2025 Aug 21. [Abstract]
- Electrophoresis. 2026 Mar 24. [Abstract]
- Electrophoresis. 2025 Sep 23. [Abstract]
- J Immunol Methods. 2023 Nov:522:113552. [Abstract]
- bioRxiv. 2026 May 27.
- bioRxiv. 2025 Oct 16.
- Research Square Preprint. 2022 Mar.
Customer Validation & Images
-
Flow Cytometry
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Flow Cytometry
-
Flow Cytometry
Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
Human IgG1 kappa
Human
|
CD20/MS4A1 |
RDC Antibody |
Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Rituximab has a significant ADCC effect on Raji cells in a dose-dependent manner.The EC50 for this effect is 6.56 and 3.25 ng/mL.
Chemical Information
-
CAS No. 174722-31-7
-
Appearance Liquid
-
Masse moléculaire 143.47 kDa
-
Color Colorless to light yellow
-
SMILES
[Rituximab]
-
Synonyms
Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. [Abstract]2020 Sep 14;5(1):200. PMID: 32929063 -
EBioMedicine
Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial. [Abstract]2024 Nov:109:105379. PMID: 39368454
Rituximab purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2024 Nov:109:105379. [Abstract]
Biological activity of ADCC response induced by trastuzumab in BT474 and SKBR3 cells upon treatment with increasing concentrations of rituximab (6 h) was measured.
-
Cancer Biol Med
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers. [Abstract]2020 Nov 15;17(4):1026-1038. PMID: 33299651
Rituximab purchased from MedChemExpress. Usage Cited in: Cancer Biol Med. 2020 Nov 15;17(4):1026-1038. [Abstract]
Namalwa cells and Daudi cells were mixed with phosphate-buffered saline, rituximab (100 nM), or 161519 TriKE (100 nM) and incubated for 30 min at 37 °C.
-
Clin Transl Med
IRF4 contributes to chemoresistance in IGH::BCL2-positive diffuse large B-cell lymphomas by mediating BCL2-induced SOX9 expression. [Abstract]2025 May;15(5):e70336. PMID: 40356256
Rituximab purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2025 May;15(5):e70336. [Abstract]
DLBCL cells were treated either with ABT-199, ABT-737, or R-CHOP (CHOP plus 10 µg/mL Rituximab) for 48 h.
-
Anal Chem
2023 Apr 25;95(16):6700-6708. PMID: 37052573 -
Anal Chim Acta
Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. [Abstract]2021 Apr 15:1154:338306. PMID: 33736796 -
Cell Rep Methods
Efficiency landscape of bioorthogonal click reactions producing bispecific antibody conjugates. [Abstract]2026 Jun 15;6(6):101416. PMID: 42019503 -
Bioconjug Chem
Resin-Supported Site-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates with Retained Efficacy and Improved Stability. [Abstract]2025 Aug 21. PMID: 40839643 -
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887 -
Electrophoresis
Towards an Analytical Procedure Control Strategy for the Capillary Zone Electrophoresis Method for Monoclonal Antibodies: Alternatives for ε-Aminocaproic Acid and Triethylenetetramine. [Abstract]2025 Sep 23. PMID: 40988426
Rituximab purchased from MedChemExpress. Usage Cited in: Electrophoresis. 2025 Sep 23. [Abstract]
Overlay of CZE electropherograms of rituximab (1 mg/mL) and infliximab analysed using 400 mM eACA, 2 mM TETA, 0.05% HPMC, pH 5.7 (blue), 400 mM GABA, 2 mM TETA, 0.05% HPMC, pH 5.7 (red), 400 mM 7-AHA, 2 mM TETA, 0.05% HPMC, and pH 5.7 (green).
-
J Immunol Methods
Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff. [Abstract]2023 Nov:522:113552. PMID: 37652294 -
-
-
Rituximab purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 Mar.
In the case of rituximab (17 nM; 48 h) killing, flow cytometry detected the proportion of cells in the G2 phase of each group.
Protocole
A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
C57BL/6 mice (8-10 wk of age) are inoculated 8×103 EL4-CD20+ cells in 200 μL of saline by tail vein injection. In parallel groups of mice, 150 g of rituximab, murine anti-CD20 IgG2a Ab 1F5, or control anti-human IL-2R Ab daclizumab in 300 μL of saline, or saline only is inoculated i.p. 24 h later[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50. [Content Brief]
[2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [Content Brief]
[3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rituximab Related Classifications
HY-P9913 Related Classifications
Powered by Bioz